Biocon Ltd is leading India’s push into weight loss drugs as patents for some of the blockbuster medications are set to expire. The pharma company has won approval from the UK regulator for the ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

“Even after India approves the coronavirus vaccine, it might not be possible to produce more than 10-20 million doses in the first year.” The comments came from the Chairperson of Biocon in an ...